DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pradaxa (Dabigatran Etexilate Mesylate) - Published Studies


Pradaxa Related Published Studies

Well-designed clinical trials related to Pradaxa (Dabigatran)

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. [2013]

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. [2011]

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. [2010]

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. [2010]

Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). [2010]

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. [2009]

Nelarabine. [2008]

Well-designed clinical trials possibly related to Pradaxa (Dabigatran)

Aspirin for prevention and treatment of venous thromboembolism. [2014]

New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. [2013]

Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. [2012]

Anticoagulating obese patients in the modern era. [2011]

Other research related to Pradaxa (Dabigatran)

Evaluation of dabigatran utilization and risk among hospitalized patients. [2014]

Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. [2014]

Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. [2014]

Warfarin or dabigatran for treatment of atrial fibrillation. [2014]

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. [2013]

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. [2013]

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. [2013]

Dabigatran: is there a role for coagulation assays in guiding therapy? [2013]

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. [2013]

Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects. [2013]

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. [2013]

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. [2013]

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. [2011]

Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. [2011]

Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. [2011]

Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice. [2010]

Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. [2010]

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. [2010]

Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. [2010]

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. [2009]

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. [2009]

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. [2008]

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). [2007]

Other possibly related research studies

Update on the management of atrial fibrillation: anticoagulation and medical therapy. [2011]

The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery? [2010]

Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? [2010]

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. [2010]

Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? [2010]

Prevention and treatment of thromboembolic events in medical patients and new anticoagulants. [2009]

New oral anticoagulants: not quite there yet. [2009]

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. [2012]

Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. [2012]

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. [2013]

New oral anticoagulants in elderly patients. [2013]

Use of new oral anticoagulants in antiphospholipid syndrome. [2013]

Implications of new anticoagulants in primary practice. [2013]

Novel oral anticoagulants in acute coronary syndrome. [2013]

Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants. [2013]

Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. [2014]

Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. [2014]

New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]

Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. [2014]

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. [2014]

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. [2014]

New oral anticoagulants and the cancer patient. [2014]

New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. [2013]

Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. [2013]

Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. [2014]

New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]

Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. [2014]

A new class of powerful and informative simultaneous confidence intervals. [2014]

Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. [2014]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017